Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
Intended for Healthcare Professionals
British Journal of General Practice

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Clinical Intelligence

Biologic agents in inflammatory arthritis

Hannah Jethwa and Sonya Abraham
British Journal of General Practice 2018; 68 (669): 204-205. DOI: https://doi.org/10.3399/bjgp18X695705
Hannah Jethwa
Ealing Hospital, London.
Roles: Specialist registrar in rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonya Abraham
Imperial College Research Facility, Hammersmith Hospital, London.
Roles: Clinical senior lecturer in rheumatology and general internal medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info
  • eLetters
  • PDF
Loading

INTRODUCTION

The term ‘inflammatory arthritis’ (IA) encompasses a spectrum of diseases, of which the most common forms are rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Over the past decade, the advent of immunomodulatory biological therapies has dramatically changed the management of such diseases, and offers alternatives for patients with a poor response to the more conventional disease-modifying anti-rheumatic drugs (DMARDs).

Over recent years, more emphasis has been placed on the concept of shared care between specialist and primary care physicians for many chronic conditions once on a stable treatment regime, in order to improve hospital workload and enable more flexibility for patients. This brief review highlights the key points relevant to primary care physicians involved in the care of patients with IA on biologic agents.

IMMUNOMODULATORY BIOLOGIC AGENTS IN INFLAMMATORY ARTHRITIS

Immunomodulatory biologic agents (Table 1) are proteins derived from human genes that are genetically engineered to inhibit precise components of the immune system.1 By doing so, they suppress specific pathways that play a pivotal role in IA pathogenesis and, hence, differ from the more commonly used DMARDs, which have broader targets.1 If tolerated, biologic agents are used in combination with methotrexate, or an alternative DMARD, in view of enhanced efficacy.

View this table:
  • View inline
  • View popup
Table 1.

Summary of biologic agents licensed for the treatment of inflammatory arthritis3,4

Biologic agents are initiated and monitored by the specialist rheumatology team and, in general, their use is recommended following either poor response or intolerance to conventional treatment options.2 Patients may be switched from one biologic to another due to intolerance (side effects or abnormal blood parameters) or poor efficacy.

Prior to prescription, patients will have been screened for history of recurrent infection or symptoms/signs of malignancy, tuberculosis (TB) risk (chest X-ray and immune test according to local protocol), and virology (hepatitis B and C/HIV/varicella IgG) due to reactivation risk.3 Screening blood tests are also performed for full blood count (FBC), liver function tests (LFTs), and lipids3 (Table 1) as biologic agents can affect these parameters.2 Guidelines recommend that all patients are up to date with varicella zoster, hepatitis B, and measles, mumps, rubella (MMR) vaccinations prior to use of biologic agents.3

‘Biosimilars’

Biosimilars are medications almost identical in structure to biologic agents produced by different pharmaceutical companies. Due to a lower production cost, biosimilars are now recommended ahead of biologic agents.

Studies thus far have shown that biosimilars have a similar mechanism of action and safety/side effect profile to the standard biologic agents.

RECOMMENDATIONS FOR BIOLOGIC AGENT MONITORING AND GENERAL ADVICE IN SHARED CARE

The most common side effect experienced by patients on biologic agents is irritation at the injection site (affecting ≤30% of patients). Allergic reactions following intravenous infusions have been reported but are infrequent.4

A flu-like illness or upper respiratory tract or gastrointestinal (GI) tract symptoms (nausea, diarrhoea) may occur. Headache has also been noted in some patients.1

As with any immunomodulatory agent, the main risk of biologic use is infection due to immunosuppression; this includes TB and fungal infections, as well as common bacterial infections.5

Key points in the care of a patient on an immunomodulatory biologic agent are summarised as follows.

General points

  • Patients should be advised to seek medical attention urgently if symptoms of infection develop.

  • Patients with symptoms of infection should stop their biologic treatment until medical advice is sought.

  • Advice should be given to avoid contact with those suffering from chickenpox or shingles.

  • Regular influenza and pneumococcal immunisations are advised.

  • Live vaccinations should be avoided; if clinically indicated, specialist advice should be sought.

  • With regards to travel, patients must ensure they are up to date with appropriate vaccinations, and caution must be taken regarding storage of biologic drugs (certain drugs need refrigeration and can only be kept at room temperature for short time durations).

  • Long-term use of certain biologic agents can increase malignancy risk, such as lymphoma and skin cancers, so a high index of suspicion is needed for timely diagnosis.

  • If LFTs are within normal limits, low-to-moderate alcohol consumption is permitted (but caution should be taken if the patient is also taking methotrexate).

  • Smoking cessation advice and support is advised because studies have shown improved efficacy of biologic agents following smoking cessation.

Holding therapy and seeking specialist advice

  • If the patient develops symptoms (for example, flu-like illness or gastrointestinal upset) following biologic dosing, this should be discussed with the specialist team if there are concerns regarding potential side effects.

  • If a patient has evidence of active infection requiring antibiotic/antifungal therapy (regardless of severity), the GP should hold the biologic agent and treat the infection urgently; advice should be sought from the specialist rheumatology team regarding when the biologic agent can be restarted.

  • Note that patients on immunosuppressive therapies may not respond to the standard short course of antibiotics and may require a longer treatment duration (refer to local antibiotic guidelines for antibiotic choice and duration).

  • If there are symptoms of viral illnesses, consider holding the biologic agent if dose is due imminently and seek advice from the rheumatology specialist team.

  • The frequency of blood monitoring should be specified by the specialist rheumatology team; if there are any relevant abnormal parameters in the blood results (such as neutropenia or elevated LFTs), advise the patient to hold their treatment and contact the specialist team for advice.

  • Biologic agents should be stopped in a timely manner prior to elective surgery, according to drug half-life, as they can impair wound healing and increase infection risk — this should be a joint decision between the surgical and rheumatology teams.

  • Some biologic agents are contraindicated in pregnancy; advice regarding pregnancy should be discussed with the specialist rheumatology team.

CONCLUSION

Primary care physicians are usually the first point of access for patients with chronic conditions. Over recent years there have been significant changes to the way IA is managed. The advent of biologic agents has provided an effective therapy for patients with poorly controlled disease on more conventional DMARDs. An understanding of biologic agents by primary care physicians is vital for a successful ‘shared care’ model for such diseases, especially with regards to identifying comorbid signs and symptoms in patients already established on treatment.

Notes

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

Discuss this article

Contribute and read comments about this article: bjgp.org/letters

  • Received October 12, 2016.
  • Revision requested November 22, 2016.
  • Accepted February 8, 2017.
  • © British Journal of General Practice 2018

REFERENCES

  1. 1.↵
    1. WebMD
    Biologics for rheumatoid arthritis treatment. https://www.webmd.com/rheumatoid-arthritis/biologics#1 (accessed 6 Mar 2018).
  2. 2.↵
    1. Smolen JS,
    2. Landewé R,
    3. Breedveld FC,
    4. et al.
    (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Royal College of Nursing
    (2017) Assessing, managing and monitoring biologic therapies for inflammatory arthritis (RCN, London), 4th edn, https://www.rcn.org.uk/professional-development/publications/pdf-005579 (accessed 6 Mar 2018).
  4. 4.↵
    1. National Rheumatoid Arthritis Society
    (2013) Biologics: the story so far (NRAS, Maidenhead) https://www.nras.org.uk/data/files/Publications/Biologics-.pdf (accessed 6 Mar 2018).
  5. 5.↵
    1. Gordon R,
    2. Mays R,
    3. Doan H,
    4. et al.
    (2012) Biologic therapy and risk of infection. Skin Therapy Lett 17(4):1–4.
    OpenUrlPubMed
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 68 (669)
British Journal of General Practice
Vol. 68, Issue 669
April 2018
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Or,
sign in or create an account with your email address
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Biologic agents in inflammatory arthritis
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Biologic agents in inflammatory arthritis
Hannah Jethwa, Sonya Abraham
British Journal of General Practice 2018; 68 (669): 204-205. DOI: 10.3399/bjgp18X695705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Biologic agents in inflammatory arthritis
Hannah Jethwa, Sonya Abraham
British Journal of General Practice 2018; 68 (669): 204-205. DOI: 10.3399/bjgp18X695705
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • INTRODUCTION
    • IMMUNOMODULATORY BIOLOGIC AGENTS IN INFLAMMATORY ARTHRITIS
    • RECOMMENDATIONS FOR BIOLOGIC AGENT MONITORING AND GENERAL ADVICE IN SHARED CARE
    • CONCLUSION
    • Notes
    • REFERENCES
  • Figures & Data
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • How to manage low testosterone level in men: a guide for primary care
  • Hyperparathyroidism (primary) NICE guideline: diagnosis, assessment, and initial management
  • The atypical presentation of COVID-19 as gastrointestinal disease: key points for primary care
Show more Clinical Intelligence

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2022 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242